In the current issue of Angiology, Visser and colleagues 1 examined the influence of metabolic syndrome (MetS) on short-and long-term outcome and survival after carotid endarterectomy (CEA). The diagnosis of MetS was established on the basis of ''the presence of 3 of the following criteria: hypertension (blood pressure >140/90 mm Hg or use of antihypertensive medication); serum triglycerides >150 mg/dL; high-density lipoprotein cholesterol <40 mg/dL in men and <50 mg/dL in women; body mass index (BMI) >30 kg/m 2 ; and fasting serum blood glucose >110 mg/dL or use of antidiabetic medication.'' 1 Of note, the authors enrolled patients with diabetes mellitus (DM) and those with overt obesity defined by BMI and not by waist circumference. 2
In the current issue of Angiology, Visser and colleagues 1 examined the influence of metabolic syndrome (MetS) on short-and long-term outcome and survival after carotid endarterectomy (CEA). The diagnosis of MetS was established on the basis of ''the presence of 3 of the following criteria: hypertension (blood pressure >140/90 mm Hg or use of antihypertensive medication); serum triglycerides >150 mg/dL; high-density lipoprotein cholesterol <40 mg/dL in men and <50 mg/dL in women; body mass index (BMI) >30 kg/m 2 ; and fasting serum blood glucose >110 mg/dL or use of antidiabetic medication.'' 1 Of note, the authors enrolled patients with diabetes mellitus (DM) and those with overt obesity defined by BMI and not by waist circumference. 2 The prevalence of MetS ranges from 10% to 40% 3 but may vary worldwide according to the geographical region, study population (age, ethnicity, and lifestyle), and definition used. [4] [5] [6] There is ample evidence that MetS is associated with an increased risk of future DM and vascular events and accumulating data showing that it may serve as a predictor of adverse outcomes in patients undergoing both cardiac and noncardiac surgery. 7 Although MetS serves as a predictor of long-term morbidity and mortality warranting global risk factor modification, 3, 8 its use as a clinical tool to identify surgery patients at risk of perioperative events remains a contentious issue
Metabolic syndrome is substantially frequent among patients with vascular disease with rates exceeding 30% in patients with evidence of carotid artery atherosclerotic disease 9 and may be as high as 50% in those with peripheral arterial disease. 10 The presence of MetS has been associated with increased morbidity and mortality following vascular surgery. 7 The study of Visser et al is the second reported largest cohort to assess the effect of MetS on postoperative outcomes of patients undergoing CEA. 1 Primary end points were defined as the occurrence of transient ischemic attack (TIA), cerebrovascular accident (CVA), myocardial infarction (MI), and mortality. A total of 564 CEAs were performed in 525 patients (mean follow-up of 46.8 months). The presence of MetS at baseline had no significant effect on both short-and long-term outcomes after CEA. The 30-day all-cause mortality rate was 1.2% (7 of 564; P ¼ .47) and the combined CVA and death rate was 5.0% (MetS 5.7% vs no MetS 4.4%; P ¼ .46). The 2-and 5-year freedom from TIA, CVA, or MI were comparable between individuals with and without MetS. 1 Contrary to previous reports, 9, 11 this study 1 concluded that the presence of MetS had no effect on the outcome after CEA. In fact, the authors claim that patients with carotid stenosis can be safely treated by CEA with a low incidence of early and late ipsilateral or contralateral neurological events and MI. Nevertheless, Visser et al showed that DM (either alone or in the context of MetS) increases the risk of ipsilateral TIA or CVA > 30 days after CEA procedure. It should be kept in mind that the majority of individuals diagnosed with MetS present with elevated plasma glucose. 12 This elevation can be in the range of either pre-DM or DM. 3 The primary cause of hyperglycemia in patients with MetS is insulin resistance. However, plasma glucose levels may be in the normal range due to compensatory hyperinsulinemia and start to rise as soon as pancreatic b-cell function declines. Thus, hyperglycemia typically is not the first indication of MetS but may develop later. 3 Nonetheless, in the consensus definition for MetS, both pre-DM and DM count as metabolic risk factors. 2 Indeed, in the study of Visser et al, DM was present in 77% of patients who fulfilled the criteria for MetS. 1 A large retrospective study 9 evaluated the impact of MetS on the outcomes of 921 patients who underwent CEA (n ¼ 750) or carotid artery stenting (n ¼ 171); patients with MetS were more likely to experience a postoperative complication than non-MetS patients (23% vs 14%, P ¼ .001). Major adverse events (MAEs) included ipsilateral stroke, MI, or death. The 30-day MAE rates were 6.7% versus 3.3% for MetS versus non-MetS (P ¼ .02). The 90-day MAE rates were 8.7% versus 4.9% for patients with MetS and non-MetS patients, respectively (P ¼ .03). However, there was no difference between patients with MetS and non-MetS patients with respect to patency, restenosis, reintervention, or survival, but a difference existed for freedom from stroke, MI, and MAE as evaluated by Kaplan-Meier analysis in an average follow-up period of 4.5 years. Notably, the presence of DM was also associated with higher rates of MAE and MI in patients with MetS compared with the non-MetS group, whereas for patients without DM, MetS was not significantly associated with MAE, stroke, or MI. 9 Another retrospective study 11 examined the records of all patients (n ¼ 79) who underwent CEA at the Veterans Affairs Connecticut Healthcare System during a 4-year period; there was no difference in the rates of 30-day stroke or MI and no significant difference for the combined end point of death, stroke, and MI during follow-up (5.2 years) between patients with and without MetS. On the other hand, the presence of MetS at the time of CEA was a significant and independent predictor of restenosis in late follow-up. 11 The study of Visser et al 1 adds useful information to the scarcity of data regarding the usefulness of MetS diagnosis as a predictor of outcome of patients undergoing carotid revascularization. Discrepancies between studies could be due to the differences in the study design and the characteristics of patient populations enrolled. With regard to MetS features, central obesity was established on the grounds of an increase in BMI instead of waist circumference as one of the components of MetS. Although current guidelines 2 favor the use of waist circumference over BMI as a more reliable criterion for the diagnosis of MetS, the use of BMI as a tool to ''measure'' upper body obesity in all 3 studies facilitates comparisons between studies. Diabetes mellitus is a well-established cause of acceleration of carotid atherosclerosis; 13 therefore, the inclusion of patients with DM is justified.
All in all, the study of Visser et al 1 provides convincing data that CEA can be safely performed in patients with or without the MetS. Among individual risk factors, DM appears to be a strong predictor of 30-day ipsilateral TIA or CVA in these patients. Besides, it is well documented that MetS as an entity is associated with both symptomatic and asymptomatic carotid atherosclerosis. 14 In line with this association, it has been demonstrated that the higher the number of MetS components, the higher the risk for developing carotid atherosclerosis and carotid plaques. 14 The identification of patients at risk of adverse outcomes following a CEA remains an important issue of clinical relevance. However, it appears that we need further data from larger prospective studies with longer follow-up periods to draw safe conclusions as to the usefulness of MetS as a predictor of postoperative risk after a carotid revascularization procedure.
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